Harbor Investment Advisory LLC Sells 523 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Harbor Investment Advisory LLC has reduced its stake in Regeneron Pharmaceuticals by 16.4%, selling 523 shares and bringing their total holdings to 2,675 shares valued at approximately $1.4 million.
• Multiple large institutional investors, including Vanguard Group Inc. and Goldman Sachs Group Inc., have increased their positions in Regeneron, reflecting strong interest, with institutional ownership currently at 83.31%.
• Regeneron reported $12.89 earnings per share for the last quarter, significantly surpassing analyst expectations, along with a revenue of $3.68 billion, resulting in an increase of 3.6% year-over-year.

Harbor Investment Advisory LLC reduced its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 16.4% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,675 shares of the biopharmaceutical company's stock after selling 523 shares during the period. Harbor Investment Advisory LLC's holdings in Regeneron Pharmaceuticals were worth $1,404,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently modified their holdings of the company. Vanguard Group Inc. grew its position in Regeneron Pharmaceuticals by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 9,407,891 shares of the biopharmaceutical company's stock worth $5,966,767,000 after acquiring an additional 121,545 shares during the last quarter. Price T Rowe Associates Inc. MD grew its position in Regeneron Pharmaceuticals by 4.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,175,026 shares of the biopharmaceutical company's stock worth $1,379,467,000 after acquiring an additional 89,579 shares during the last quarter. Amundi grew its position in Regeneron Pharmaceuticals by 3.4% during the 1st quarter. Amundi now owns 1,603,901 shares of the biopharmaceutical company's stock worth $979,794,000 after acquiring an additional 52,166 shares during the last quarter. Goldman Sachs Group Inc. grew its position in Regeneron Pharmaceuticals by 18.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,143,093 shares of the biopharmaceutical company's stock worth $724,984,000 after acquiring an additional 174,056 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Regeneron Pharmaceuticals by 30.1% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 982,064 shares of the biopharmaceutical company's stock valued at $699,554,000 after buying an additional 226,952 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have commented on REGN. Morgan Stanley reiterated an "overweight" rating and issued a $761.00 price objective (up from $754.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Jefferies Financial Group increased their price objective on Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the company a "buy" rating in a research report on Wednesday, August 27th. BMO Capital Markets increased their price objective on Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the company an "outperform" rating in a research report on Monday, August 4th. Canaccord Genuity Group reiterated a "buy" rating and issued a $850.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Wednesday, July 23rd. Finally, Citigroup reiterated a "buy" rating and issued a $650.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Three analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $817.67.

Regeneron Pharmaceuticals Stock Performance

REGN stock opened at $560.00 on Friday. The business's fifty day moving average is $564.61 and its 200-day moving average is $578.77. The company has a quick ratio of 3.72, a current ratio of 4.60 and a debt-to-equity ratio of 0.09. The company has a market cap of $59.35 billion, a P/E ratio of 14.11, a price-to-earnings-growth ratio of 1.90 and a beta of 0.35. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $1,170.58.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, beating analysts' consensus estimates of $8.43 by $4.46. The company had revenue of $3.68 billion for the quarter, compared to the consensus estimate of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The firm's quarterly revenue was up 3.6% on a year-over-year basis. During the same quarter in the prior year, the business posted $11.56 EPS. Equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Monday, August 18th were paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend was Monday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.87%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.